Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00543842 · ClinicalTrials.gov registry record · Phase 1
Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT00543842: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00543842 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00543842, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of bevacizumab (Avastin) and erlotinib hydrochloride (Tarceva) that can be given in combination with standard radiation therapy and capecitabine before surgery to patients with rectal cancer. The safety and effectiveness of this combination of therapies will also be studied. The goal of this Phase I trial was to determine the maximal tolerated dose (MTD) of concurrent capecitabine, bevacizumab and erlotinib with preoperative radiation therapy (RT) for rectal cancer. The trial completed as Phase I without progressing to the Phase II portion.
Interventions
- DRUG Bevacizumab
- DRUG Capecitabine
- RADIATION Radiation Therapy
- PROCEDURE Surgery
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2007-12 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00543842
The ClinicalTrials.gov registry entry for NCT00543842 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT00543842 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00543842 about?
NCT00543842 is a clinical study titled "Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer". The goal of this clinical research study is to find the highest tolerable dose of bevacizumab (Avastin) and erlotinib hydrochloride (Tarceva) that can be given in combination with standard radiation therapy and capecitabine before surgery to patients with rectal cancer. The safety and effectiveness ...
What is the current status of trial NCT00543842?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2007-12. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00543842?
The interventions under investigation include: Bevacizumab (DRUG), Capecitabine (DRUG), Radiation Therapy (RADIATION), Surgery (PROCEDURE), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00543842?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.